The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers

Prostate cancers in patients with a mutation in BRCA2 have earlier disease onset and an aggressive course, often necessitating the use of systemic therapy. However, these tumours are DNA repair-defective and could respond favourably to Parp inhibitors or DNA-damaging agents, depending on the therape...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Vesprini, Danny, Narod, Steven A, Trachtenberg, John, Crook, Juanita, Jalali, Farid, Preiner, John, Sridhar, Srikala, Bristow, Robert G
Format: Artigo
Idioma:Inglês
Publicat: Canadian Medical Association 2011
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3104437/
https://ncbi.nlm.nih.gov/pubmed/21470549
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.10080
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars